# OnCo record nct05417594 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05417594/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05417594", "NCT05417594" ;
  schema:name "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies"@en ;
  schema:alternateName "CERTIS1"@en ;
  schema:description "A phase 1/2 trial of Palacaparib, Temozolomide, Trastuzumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05417594/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05417594> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-06-24" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/palacaparib/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .